Loading clinical trials...
Loading clinical trials...
A Randomized, Controlled, Multi-center Phase III Clinical Study of AK112 Plus Nab-paclitaxel Versus Placebo Plus Nab-paclitaxel as First-line Treatment for Locally Advanced Unresectable or Metastatic Triple-negative Breast Cancer
Conditions
Interventions
AK112
Nab-paclitaxel
+1 more
Locations
1
China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
Start Date
February 7, 2025
Primary Completion Date
December 1, 2026
Completion Date
December 1, 2028
Last Updated
March 16, 2026
NCT07073755
NCT06975644
Lead Sponsor
Akeso
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions